Status:
COMPLETED
Patient and Physician Knowledge of Key Safety Messages
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
RTI Health Solutions
Conditions:
Anticoagulation
Eligibility:
All Genders
18+ years
Brief Summary
This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.
Eligibility Criteria
Inclusion
- \- Inclusion criteria:
- Physician eligibility:
- Prescription of rivaroxaban in the past 6 months for adult patients for the Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (SPAF) or Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT.
- Patient eligibility:
- Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and above; able to understand and complete the consent form and patient questionnaire.
Exclusion
Key Trial Info
Start Date :
September 15 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2020
Estimated Enrollment :
2227 Patients enrolled
Trial Details
Trial ID
NCT01907048
Start Date
September 15 2014
End Date
April 15 2020
Last Update
April 8 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, France
2
Multiple Locations, Germany
3
Multiple Locations, Spain
4
Multiple Locations, United Kingdom